Emcure Pharmaceuticals Limited CC-Jun25.pdf · 2025-08-07
Is it possible to give some flavour on how the Sanofi Cardiac portfolio is doing for you or 1Q of this year compared to last year?
And on the additional diabetic portfolio that you acquired from Sanofi, is it possible to understand the rationale, are these drugs not generally not seeing a slower sort of growth given that we've had a new generation of drugs coming in for diabetes or these still constitute the first line of treatment and therefore, will you expect them to grow healthily?